Brief: Ultimovacs Provides Results From Testing Of UV1

Zelluna ASA

04/06/2021 14:18

June 4 (Reuters) - Ultimovacs ASA  ULTIMO.OL :
    * ULTIMOVACS ASCO PHASE I DATA SHOWS 60% ORR IN ADVANCED
MELANOMA
WITH UV1/PEMBROLIZUMAB\, SUPPORTING BROAD PHASE II COMBINATION
PROGRAM
    * DATA ALSO SHOWS THAT UV1/PEMBROLIZUMAB COMBINATION IS SAFE
AND
WELL TOLERATED
    * TWO YEAR FOLLOW UP ON FIRST COHORT WILL ALSO BE REPORTED
IN Q4
2021

Source text for Eikon:  ID:nObikXgRka 
Further company coverage:  ULTIMO.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))